Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Dalteparin may stop the growth of cancer by stopping blood flow to the tumor and
by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy
x-rays to damage tumor cells. Combining dalteparin with radiation therapy may kill more tumor
cells.
PURPOSE: Phase II trial to study the effectiveness of combining dalteparin with radiation
therapy in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.